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Introduction
Uveitis, particularly posterior uveitis, is a sight-threatening intraocular inflammatory disease, it can occur in isolation or associated with other systemic immunological diseases such as Vogt-Koyanagi-Harada disease and Behçet's disease. Experimental autoimmune uveitis (EAU) in the mouse closely resembles the pathology of human posterior intraocular inflammatory conditions such as sympathetic ophthalmia, sarcoidosis, and birdshot retinochoroidopathy [1, 2] . The pathology of EAU is mediated by autoantigen-specific CD4 + T cells whose activation is accompanied by the infiltration of tissue damaging leukocytes, such as macrophages and neutrophils, into the retina/choroid [3] . Both Th1 and Th17 cells are thought to be responsible for the disease [4] while Th2 and regulatory T cells can protect against EAU [5] . Previously, we have reported different phenotypes of macrophages in the retina tissues during disease progression from peak to later stages of EAU [6] . While some macrophages, e.g. sialoadhesin positive macrophages, can exacerbate the inflammatory response in EAU [3] , other types of macrophages are associated with suppression of the disease [3, 7] . Here, we have investigated the role of IL-33 [8] , the recently identified type 2 cytokine, in EAU and the effect of IL-33 on the phenotypic changes of T cells and macrophages during the disease development. IL-33 is a member of the IL-1 cytokine family, which also includes IL-1α, IL-1β, IL-18, and IL-1Ra. Different from IL-1 and IL-18, full length IL-33 is bioactive and is released through cell necrosis [9] or via vesicles in endothelial cells and fibroblasts [10] . IL-33 signals via the heterodimeric receptor consisting of ST2 and IL-1R accessory protein [11] . The membrane form of ST2, encoded by the ST2 gene [12] , is expressed on cells including activated Th2 cells [13] and mast cells [14] . ST2 is alternatively spliced to produce a soluble form (sST2), which acts as a decoy receptor of IL-33 [15] . Human IL-33 was detected in epithelial cells, fibroblasts [8] , and endothelial cells of inflamed tissues from patients with rheumatoid arthritis and Crohn's disease [16] . In rodents, Il33 mRNA was detected in various tissues and organs including lungs, lymph nodes, spleens, and the CNS [8] . IL-33 has pleiotropic effects on immune responses [17] and plays an important role in the development of many immune-mediated diseases. Previous studies using in vivo disease models have shown that IL-33 exacerbates allergic inflammation [18] but confers resistance to parasite infection [19] and attenuates atherosclerosis [20] through inducing type 2 immune responses. However, IL-33 is also able to induce inflammatory hypernociception [21] and is a proinflammatory cytokine in both antigen-and autoantibody-induced arthritis via activating mast cells [17, 22, 23] . Recent studies show that the IL-33/ST2 pathway plays a significant role in the amplification of alternatively activated macrophage (M2) polarization. M2 appears to play a key role in IL-33-mediated exacerbation of airway inflammation [24] , protection against obesity-related metabolic events [25] , and attenuation of EAE [26] .
IL-33 has been detected in normal conjunctivae and human vascular endothelial cells of giant papillae formations in allergic conjunctiva [27] . However, the role of IL-33 in the development of retinal inflammatory diseases is hitherto unknown. In the present study, we show that IL-33 protein is highly expressed in retinal cells, and the expression is markedly upregulated in EAU mice. Furthermore, we found that ST2-deficient (ST2 −/− ) mice developed more severe retinal inflammation compared with WT mice, 
Results

Expression and function of IL-33 in the RPE cells
It is well documented that many epithelial cells in tissues express IL-33 [8] . Retinal pigment epithelial (RPE) cells are an important component of the blood retina barrier, which is central to retinal homeostasis and involved in the development of many retinal diseases. We first examined the expression of IL-33 in an established murine RPE cell line [28] . Cells cultured in cell chamber slides were used for immunohistochemical staining and cells cultured in flasks were harvested for flow cytometry analysis. Our data show that RPE cells expressed high levels of IL-33 as well as its receptor ST2 (Fig. 1A and B 
IL-33 expression in naïve and EAU eye tissues
To identify the expression of IL-33 in vivo, we next examined the expression of IL-33 in the normal eye tissues as well as tissues from EAU mice. EAU was induced as described in "Materials and methods." IL-33 was expressed by cells in the inner nuclear layer (INL) of retina tissues from naïve C57BL/6 mice ( Fig. 2A and B) . Because of the dark pigment in the RPE cells and in the choroid in C57BL/6 mice, we used fluorescence immunohistochemical staining to study the expression of IL-33 in the retina of both C57BL/6 and BALB/c mice. Data in Figure 2C and D confirmed IL-33 expression in INL cells in the retina of both strains of mice. Interestingly, IL-33 expression levels in the RPE cells were strain dependent, while RPE cells in C57BL/6 mice expressed low levels of IL-33 ( Fig. 2C and E), the expression was higher in the RPE cells of nonpigmented BALB/c mice ( Fig. 2D and F) . In the retina tissue from EAU mice (day 16 postimmunization) of the C57BL/6 background, the expression of IL-33 was markedly increased in the INL with an increased number of IL-33 positive cells, and these cells moved toward the outer nuclear layer (Fig. 2G-I ). Similar levels of IL-33 expression were also observed in eye tissues harvested at day 21 after immunization. These results indicate that the expression of IL-33 is closely associated with EAU.
Recombinant IL-33 treatment attenuate EAU development
To directly assess the role of IL-33 in EAU development, we administered recombinant IL-33 i.p. to IRBP-immunized mice as described in the "Material and methods." On day 18 after immunization, PBS-treated control mice developed retinal inflammation with swelling of the optic disc, diffuse whitish retinal exudates in the retina, and signs of vessel inflammation (vasculitis) (Fig. 3A) . In contrast, the retina of the IL-33-treated mice had significantly less inflammation (Fig. 3B ). IL-33-treated mice showed a significant reduction in the clinical score compared to the control PBStreated mice (Fig. 3C ). The clinical findings were confirmed by histological examination of the eyes 25 days after immunization. Vasculitis and marked cell infiltration in the retina were observed in the retina of PBS-treated mice (Fig. 3D ), while minimal evidence of inflammation was seen in IL-33-treated mice (Fig. 3E) . IL-33-treated EAU mice developed significantly less retinal inflammation with reduced pathological scores (Fig. 3F) . Together, these results demonstrate a significant beneficial effect of IL-33 in EAU.
ST2
−/− mice develop exacerbated EAU
To identify an endogenous role of IL-33 in EAU, we next investigated the development of retinal inflammation in ST2 −/− mice.
WT and ST2 −/− mice of the C57BL/6 background were immunized and then treated with PBS or IL-33 as above. Retinal inflammation was evaluated on day 20 after immunization using the fundus imaging system. As expected, WT mice developed optic disc swelling with diffuse and localized inflammation in the retina ( www.eji-journal.eu and massive infiltration. The disease in the ST2 −/− mice was not attenuated by treatment with IL-33 ( Fig. 4D) . These results therefore demonstrate an endogenous role of IL-33 in protecting mice against uveitis.
IL-33 alters the cytokine production profile of leukocytes in EAU mice
To investigate the immunological mechanisms underpinning the role of IL-33 in EAU, we examined the cytokine production by T-cell from IL-33-treated mice, but not PBS-treated mice, significantly suppressed IL-17 production by the spleen cells from EAU mice (Fig. 5C ).
IL-33 treatment increases MR + PDL2 + M2 macrophage populations
Because of the well-defined role of IL-33 in macrophage polarization toward an M2 phenotype [29] , and the potential protective role of M2 in tissue inflammation [30] , we analyzed the macrophage phenotype in EAU mice with or without IL-33 treatment. WT C57BL/6 mice were immunized and treated with IL-33 or PBS as above and single-cell suspensions were prepared from the spleen and DLN tissues of mice 21 day after immunization. Cells were then stained for cell surface F4/80 (macrophage), CD206 (MR, mannose receptor) and CD273 (PD-L2), two markers closely identified with M2 [31] . Macrophages from IL-33-treated mice had significantly increased frequency of PD-L2 + and MR + /PD-L2 + cells in the LN and the spleen compared to that of the control PBS-treated mice (Fig. 5D) . These results therefore indicate that IL-33 treatment facilitates the polarization of M2, which may additionally account for the IL-33-mediated reduction of retina inflammation in EAU.
Discussion
Data presented here demonstrate that IL-33 has a protective effect on intraocular inflammation in EAU. In mice lacking the IL-33 IL-33 is constitutively expressed in normal epithelial and endothelial cells in tissues such as human colon, lung, liver, and skin [8, 16] , as well as in human vascular endothelial cells in allergic papillary conjunctivitis [32] . We show here the presence of IL-33 and ST2 in cultured RPE cells and demonstrated an autocrine upregulation of IL-33 in these cells. Many RPE-derived molecules are known to be involved in local immune privilege in the eye [33] ; our findings here suggest that IL-33 may also be a key immune-regulatory mediator in this context. LPS induced significantly higher expression of both Il33 and Mcp1 mRNA suggesting that the induction of EAU with CFA may well be a competitive balance between pro-and anti-inflammatory signals of innate immunity. We also found that the levels of IL-33 expression in the RPE cells in retina tissues vary in different strains of mice. While IL-33 is highly expressed by the RPE cells in the naïve BALB/c mice, the expression level was low in these cells in the naïve C57BL/6 background mice. This observation is consistent with a protective role of IL-33 in retinal inflammation as BALB/c mice are resistant whereas C57BL/6 mice are susceptible to EAU [34, 35] . Further immunohistochemical staining in the retina of naïve mice shows that that IL-33 was also constitutively expressed by cells in the INL of retina, suggesting IL-33 may have eye-specific functions under homeostasis and disease conditions. Our data of IL-33 staining in the INL also agree with a recent report that used an IL-33-LacZ gene trap reporter [36] . The author further suggested that the IL-33-positive cells are likely to be Muller glial cells. Since microglia cells also exist in the INL of retina, it would be interesting to confirm whether they also express IL-33 in the retina tissues. IL-33 expression in the retina was elevated with increased numbers of IL-33 + cells moved toward the outer nuclear layer during EAU. These data indicate that IL-33 is closely associated with the posterior inflammation of the eye, and hence might contribute to its immune regulatory role in ocular inflammation. The elevated expression of IL-33 in the retina of EAU mice may represent a failed attempt by the mice to contain EAU, which can be effectively ameliorated with additional exogenously administered recombinant IL-33. IL-33 plays an important role in many inflammatory diseases but its effect is model-and disease-specific [17] . While IL-33 exacerbates autoimmune collagen-induced arthritis via mast cell degranulation [22] , it also promotes type 2 immune responses with the production of high levels of IL-5 and IL-13 [20] and drives M2 macrophage differentiation thus protecting mice from EAE [26] and atherosclerosis [20] . However, by doing so, IL-33 contributes to the pathogenesis of asthma, atopic dermatitis, and allergic conjunctivitis [18, 27] . Data reported here suggest that IL-33 is protective against retinal inflammation, and the effect is likely to be endogenous as ST2 −/− mice developed more severe EAU. Although the relative importance of Th1 and Th17 cells in the development of autoimmunity is still debated, the current view suggests a more complex relationship between the two cell subsets; they have overlapping and differential roles [1] in the pathogenesis of EAU and other autoimmune diseases such as EAE [37] . Classically activated macrophages are often involved in tissue damage during early and peak stages of inflammatory diseases, while regulatory M2 macrophages that appear in late stages can significantly limit the damage [29, 30, 38] . It is generally agreed that a shift in T-cell and cytokine profile toward a type 2 phenotype and the emergence of regulatory T cells [39] [40] [41] are responsible for disease protection in EAE and EAU [5, 42] . While we did not observe an apparent increase of FoxP3 + Treg cell population in the lymphoid organs of IL-33-treated mice, it is likely that IL-33 reduces retinal inflammation via the reduction of Th1 and Th17 cells and skewing the immune response toward noninflammatory, protective type 2 responses. As IL-33 is also important in activating antigen presenting cells [43, 44] or innate lymphoid cells [45] to induce Th2 type responses, it may have attenuated the severity of EAU through inhibiting both the innate and the adaptive immune responses, e.g. switching the phenotype of antigen presenting DCs and macrophages in the peripheral lymphoid organs, and the microglia cells in the target retina. EAU shares many features of clinical uveitis. Data presented here that IL-33 plays an endogenous tissue protective role in EAU and IL-33 administration ameliorates EAU, suggest that IL-33 may be a potential option for treating clinical uveitis.
Materials and methods
Mice and reagents
C57BL/6 and BALB/c mice were purchased from Harlan (UK) and maintained at the Biological Procedure Unit, University of Strathclyde and University of Aberdeen. ST2 −/− mice on C57BL/6 background were described previously [20] . ST2 −/− and the WT 
RPE cell culture and qPCR
RPE cell line (B6-RPE07) was derived from a 12-week-old naïve female C57BL/6 mouse and generated as described previously [28] . Cells were cultured in T75 flasks in complete DMEM containing 10% (v/v) fetal calf serum (Sigma) and incubated in 5% CO 2 at 37°C. Seventy percent confluent cells were detached from flasks using 0.25% trypsin-EDTA and cultured in 24-well plates with different concentrations of IL-33 (10-100 ng/mL) or LPS (100 ng/mL, Sigma) for 24 h. Cells were then collected and lysed with RNA lysis buffer (Ambion, Life Technologies) for analysis of Il33 and Mcp-1 mRNA expression using Fast SYBR R Green real time PCR.
EAU induction and clinical evaluation
EAU was induced as described previously [3] . In brief, WT or ST2 −/− C57BL/6 mice were immunized subcutaneously on the lower back with 300 mg of IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] peptide (Sigma Genosys) in 50 μL of PBS emulsified with an equal volume of CFA (4 mg/mL Mycobacterium tuberculosis, strain H37RA, Difco, Detroit MI). Each mouse also received i.p. 500 ng/200 mL of pertussis toxin (PTX, Sigma) in PBS. To investigate the effect of IL-33 on EAU development, WT mice were injected i.p. every other day with IL-33 (0.5 μg/100 μL) from day 9 to 25 after the initial immunization. Control WT mice received the same volume of PBS. Clinical evaluation of ocular inflammation was performed using the fundus imaging system as previously described [46] . Briefly, mice were anesthetized and pupils were dilated before taking images, and viscoelastic material was used as medium for corneal surface during imaging.
Histological evaluation of disease
Mice were euthanized in CO 2 chamber and their eyes were carefully removed and fixed in 2.5% (w/v) glutaraldehyde and embedded in resin for standard H&E staining. In some experiments, removed eyes were snap frozen in tissue freezing optimum cutting temperature medium on dry ice for cryosectioning, H&E or immunohistochemical staining.
Immunohistochemical staining
RPE cells were cultured in cell chambers and stained with anti-IL-33 antibody (R&D Systems). Eye tissues of naïve and EAU mice (day 16 after immunization) were frozen in optimum cutting temperature and 8 μm sections were stained with anti-IL-33 antibody, followed by incubation with biotinylated secondary antibody (Vector Laboratories) and detected with substrates (DAB or AMEC from Vector Laboratories). For fluorescence staining, TRITCconjugated strepavidin was added to the tissues sections following incubation with the secondary antibody. Fluorescence staining sections were mounted with Vectashield containing DAPI (Vector Laboratories). Isotypes with matching IgG (R&D Systems) were used as negative controls.
DLN and spleen cell culture
DLN and spleen were collected and pooled within groups or analyzed individually. Single-cell suspensions were cultured in 24-well plates at 4 × 10 6 cells/2 mL per well and stimulated with medium alone or with 50 μg/mL of IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] peptide. After 72 h, supernatants were collected and concentrations of selected cytokines were measured by ELISA using paired antibodies (eBioscience).
T-cell-EAU splenocyte co-culture
Mice were treated with five doses of IL-33 (0.5 μg/100 μL) or PBS every second day. Spleen and LNs were harvested and pooled within each group. Single-cell suspensions were collected and CD4 + T cells were purified using CD4 + T-cell isolation kit II (Miltenyi Biotec, UK). Purified T cells (1 × 10 6 ) were co-cultured (in 24-well pates, 2 mL per well) with 2 × 10 6 spenocytes of day 18 EAU mice in the presence of 50 μg/mL IRBP peptide. After 72 h, supernatants were harvested for IL-17 ELISA.
Flow cytometry analysis
Antibodies were purchased from BD Pharmingen unless mentioned otherwise. RPE cells were harvested and washed before staining with anti-IL-33 (R&D System) or ST2 (MD Biosciences) antibodies. To examine the leukocyte phenotype in the DLN and spleen, single-cell suspensions were stained with anti-F4/80, anti-CD206 (MR, Serotec) and anti-CD273 (PD-L2, eBioscience) antibodies. For measurement of intracellular cytokines, cells were restimulated with 50 ng/mL phorbol-12-myristate-13-acetate and 500 ng/mL ionomycin (both from Sigma) in the presence of GolgiStop (BD Bioscience) for 4 h. Cells were then harvested and stained with cell surface anti-CD4 antibody before being permeabilized with Perm/Fix solution (eBioscience) and finally stained with anti-IL-17A (clone eBio17B7), anti-IFN-γ (clone XMG1.2), anti-IL-5 (TRFK4), and anti-IL-4 (clone 11B11) antibodies (eBioscience). Isotype-matched IgG antibodies from eBioscience were used as negative controls. Cells were analyzed by FACS Calibur using CellQuest software (BD Biosciences).
Statistical analysis
Statistical evaluations of cell frequency, cytokine production, and histological analysis were performed with the two-tail unpaired Student's t-test or Mann-Whitney test. p < 0.05 was considered statistically significant. All experiments were repeated at least twice.
